SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 24, 2002
INCARA PHARMACEUTICALS CORPORATION
----------------------------------
(Exact name of registrant as specified in its charter)
Delaware
--------
(State or other jurisdiction of incorporation)
0-27410 56-1924222
--------------- ----------
(Commission File Number) (IRS Employer ID Number)
P.O. Box 14287
79 T. W. Alexander Drive
4401 Research Commons, Suite 200
Research Triangle Park, North Carolina 27709
--------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 558-8688
--------------
Item 5. Other Events and Regulation FD Disclosure
On September 24, 2002, Incara Pharmaceuticals Corporation received
notice from the Nasdaq Listing Qualifications Panel of its determination to
delist Incara's common stock from the Nasdaq National Market at the opening of
trading on September 25, 2002 because of Incara's failure to meet the minimum
bid price, minimum market value of publicly held securities and minimum net
tangible assets requirements. Incara's common stock will now be traded on the
OTC Bulletin Board under the symbol, "INCR."
Item 7. Financial Statements and Exhibits
(c) Exhibits
Exhibit 99.1 Press release dated September 25, 2002 announcing
the Nasdq delisting
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.
INCARA PHARMACEUTICALS CORPORATION
Date: September 25, 2002
/s/ RICHARD W. REICHOW
-----------------------------------
Richard W. Reichow, Executive Vice President
and Chief Financial Officer
3